Background: Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose. Methods: This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed. Results: A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P < .001). Conclusions: In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.
Background: Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose. Methods: This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed. Results: A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P < .001). Conclusions: In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.
Authors: Borja Quiroga; María José Soler; Alberto Ortiz; Shaira Martínez Vaquera; Carlos Jesús Jarava Mantecón; Gustavo Useche; María Gabriela Sánchez Márquez; Manuel Carnerero; María Teresa Jaldo Rodríguez; Patricia Muñoz Ramos; Juan Carlos Ruiz San Millán; Nestor Toapanta; Carolina Gracia-Iguacel; María Cinta Aguilar Cervera; Noelia Balibrea Lara; Alba Leyva; José Rojas; Ron T Gansevoort; Patricia de Sequera Journal: Nephrol Dial Transplant Date: 2022-09-22 Impact factor: 7.186
Authors: José Jesús Broseta; Diana Rodríguez-Espinosa; Elena Cuadrado; Néstor Rodríguez; José Luis Bedini; Francisco Maduell Journal: Vaccines (Basel) Date: 2022-03-27
Authors: Edward J Carr; Mary Wu; Ruth Harvey; Emma C Wall; Gavin Kelly; Saira Hussain; Michael Howell; George Kassiotis; Charles Swanton; Sonia Gandhi; David Lv Bauer; Roseanne E Billany; Matthew Pm Graham-Brown; Joseph Beckett; Katherine Bull; Sushma Shankar; Scott Henderson; Reza Motallebzadeh; Alan D Salama; Lorraine Harper; Patrick B Mark; Stephen McAdoo; Michelle Willicombe; Rupert Beale Journal: Lancet Date: 2021-08-13 Impact factor: 79.321
Authors: Nick Andrews; Elise Tessier; Julia Stowe; Charlotte Gower; Freja Kirsebom; Ruth Simmons; Eileen Gallagher; Simon Thelwall; Natalie Groves; Gavin Dabrera; Richard Myers; Colin N J Campbell; Gayatri Amirthalingam; Matt Edmunds; Maria Zambon; Kevin Brown; Susan Hopkins; Meera Chand; Shamez N Ladhani; Mary Ramsay; Jamie Lopez Bernal Journal: N Engl J Med Date: 2022-01-12 Impact factor: 91.245
Authors: Alex Dulovic; Monika Strengert; Gema Morillas Ramos; Matthias Becker; Johanna Griesbaum; Daniel Junker; Karsten Lürken; Andrea Beigel; Eike Wrenger; Gerhard Lonnemann; Anne Cossmann; Metodi V Stankov; Alexandra Dopfer-Jablonka; Philipp D Kaiser; Bjoern Traenkle; Ulrich Rothbauer; Gérard Krause; Nicole Schneiderhan-Marra; Georg M N Behrens Journal: Emerg Infect Dis Date: 2022-02-24 Impact factor: 6.883
Authors: Borja Quiroga; María José Soler; Alberto Ortiz; Amparo Bernat; Ana Beatriz Muñoz Díaz; Carlos Jesús Jarava Mantecón; Virginia Olinda Gómez Pérez; Carmen Calderón González; Michal Cervienka; Auxiliadora Mazuecos; Juan Manuel Cazorla; Manuel Carnerero Di Riso; Shaira Martínez; Mayra Ortega Diaz; Rafael Lucena Valverde; María Gabriela Sánchez Márquez; Carolina Lancho Novillo; Emilio González Parra; Carolina Gracia-Iguacel; María Teresa Rodrigo De Tomas; María Cinta Aguilar Cervera; Martín Giorgi; Patricia Muñoz Ramos; Nicolás Macías Carmona; Néstor Toapanta; Secundino Cigarrán; Juan Carlos Ruiz San Millán; Raquel Santana Estupiñán; Marta Crespo; Blanca Villacorta Linaza; María Isabel Jimeno Martín; Laura Rodríguez-Osorio Jiménez; Sagrario Soriano; Dioné González Ferri; María Soledad Pizarro Sánchez; Alejandra Yugueros; Alba Leyva; José Rojas; Ron T Gansevoort; Patricia de Sequera Journal: Nephrol Dial Transplant Date: 2022-04-25 Impact factor: 7.186